

Wyeth Limited*

Registered Office :

Level 6, Platina, Plot No. C-59, G-Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 098, INDIA
Tel : 91-22-2657 4000 Fax : 91-22-2657 4100

*(A subsidiary of Pfizer Inc.)

Wyeth

August 5, 2011

The Stock Exchange, Mumbai
Corporate Relationship Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Towers
Dalal Street, Fort
MUMBAI-400 001

By Fax # 2272 3121/2272 2037/
2272 2039/2272 2041/2272 2081
& Hand Delivery

Dear Sirs :

**Sub: Unaudited Financial Results (Provisional) for the quarter ended
June 30, 2011.**

In terms of Clause 41 of the Listing Agreement, we forward herewith a copy of the Unaudited Financial Results (Provisional) of the Company for the first quarter and three months ended June 30, 2011 approved by the Board of Directors at their meeting held today. This has been subjected to a Limited Review by Messrs. B S R & Associates, the Auditors of the Company. The Limited Review Report will be submitted by August 14, 2011 in accordance with the Listing Agreement.

Necessary arrangements for publication of the said Results have been made.

Kindly acknowledge receipt.

Thank you,

Yours very truly,
WYETH LIMITED



(Mrs.) N.N. Thakore
Company Secretary &
Legal Director

Encls. a/a

Cc : National Stock Exchange of India Limited
Exchange Plaza, 5th Fl.
Plot No. C/1, G Block
Bandra - Kurla Complex,
Bandra (E)
MUMBAI - 400 051.

By Fax # 26598237/38
26598348/ 6641 8124/25/26
& Hand Delivery

Wyeth Limited*

Registered Office :
Level 6, Platina, Plot No. C-59, G-Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 098. INDIA
Tel : 91-22-2657 4000 Fax : 91-22-2657 4100

*(A subsidiary of Pfizer Inc.)


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2011

(₹ in lakhs)

Particulars	Quarter ended	Quarter ended	Sixteen months period 1st December 2009 to 31st March 2011
	30.06.2011	31.05.2010	31.03.2011
	Unaudited		Audited
1. (a) Gross Sales/Income from Operations	15057	12513	65303
(b) Less: Excise Duty	413	308	1655
(c) Net Sales/Income from Operations	14644	12205	63648
(d) Other Operating Income	136	(8)	322
2. Total Income from Operations	14780	12197	63970
3. Expenditure			
(a) (Increase)/decrease in stock-in-trade and work-in-progress	(929)	807	(335)
(b) Consumption of raw materials	1438	1280	7432
(c) Purchase of traded goods	4172	2261	14214
(d) Employees cost	962	1662	5508
(e) Depreciation	156	162	899
(f) Advertisement and sales promotion	749	396	3342
(g) Other expenditure	2824	2054	11272
(h) Total	9372	8622	42332
4. Profit from Operations before Other Income and Interest	5408	3575	21638
5. Other Income	608	291	1991
6. Profit before Interest	6016	3866	23629
7. Interest	15	10	62
8. Profit from Ordinary Activities before tax	6001	3856	23567
9. Tax Expense			
- Current tax	1,828	1050	7007
- Deferred tax	(76)	141	31
10. Net Profit from Ordinary Activities after tax	4249	2665	16529
11. Paid-up equity share capital (Face value ₹10 each)	2272	2272	2272
12. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year			36205
13. Earnings Per Share (EPS) - Basic and Diluted (₹ per equity share of ₹10 each - not annualised)	18.70	11.73	72.75
14. Public shareholding			
- Number of shares	11,105,957	11,105,957	11,105,957
- Percentage of shareholding	48.88	48.88	48.88
15 Promoters and promoter group shareholding			
(a) Pledged/encumbered			
- Number of shares	-	-	-
- Percentage of shares to the total shareholding of promoter and promoter group	-	-	-
- Percentage of shares to the total share capital of the company	-	-	-
(b) Non-encumbered			
- Number of shares	11,614,102	11,614,102	11,614,102
- Percentage of shares to the total shareholding of promoter and promoter group	100.00	100.00	100.00
- Percentage of shares to the total share capital of the company	51.12	51.12	51.12

SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED

(₹ in lakhs)

Particulars	Quarter ended	Quarter ended	Sixteen months period 1st December 2009 to 31st March 2011
	30.06.2011	31.05.2010	31.03.2011
	Unaudited		Audited
Segment Revenue			
Pharmaceuticals	13777	10979	58315
Others*	1003	1218	5655
Total	14780	12197	63970
Less: Inter Segment Revenue	-	-	-
Net Sales/Income from Operations	14780	12197	63970
Segment Results			
Profit before Interest and Taxation from each Segment			
Pharmaceuticals	5395	3349	21274
Others*	13	226	364
Total	5408	3575	21638
Less: Interest Expense	(15)	(10)	(62)
Add: Other Income	608	291	1991
Total Profit before Taxation	6001	3856	23567
Capital Employed			
Pharmaceuticals	10669	11845	13040
Others*	89	11	(201)
Total	10758	11856	12839
Add: Unallocable corporate assets less unallocable corporate liabilities	31967	21619	25637
Total capital employed	42725	33475	38476

* Others comprise of OTC pharmaceuticals, Cosmetics and other allied consumer products.

Ah

9.

Q

Notes:


1. The above results were reviewed and recommended by the Audit Committee for approval by the Board at its meeting held on 5th August, 2011 and were approved at the meeting of the Board of Directors held on that date.
2. The company has changed its accounting year from 1st December - 30th November to 1st April - 31st March with effect from 1st December, 2009. The current quarter is from 1st April 2011 to 30th June 2011, while the previous quarter was from 1st March 2010 to 31st May 2010. Hence the figures are not strictly comparable. The previous period was for 16 months from 1st December 2009 - 31st March 2011.
3. (a) The results for the quarter ended 30th June, 2011 have been subjected to a limited review by the statutory auditors of the Company.

(b) The Government of India demanded amounts aggregating to ₹5907.72 lakhs (inclusive of total interest of ₹4206.36 lakhs) upto 31st March, 2008 from the Company under the Drugs (Prices Control) Order (DPCO), 1979.

The Hon'ble Bombay High Court vide its interim orders dated 10th June, 2008 and 10th July, 2008 in the matters of De-Methyl-Chloro-Tetracycline Hydrochloride and Benzathine Penicillin G respectively, directed the company to deposit the principal amounts and furnish security for the interest thereon. Accordingly, the company has deposited the principal amounts aggregating to ₹1568.03 lakhs with the Prothonotary & Senior Master, High Court, Bombay and furnished corporate bonds for amounts aggregating to ₹4019.02 lakhs for interest thereon in favour of the Prothonotary & Senior Master, High Court, Bombay. The matters are pending adjudication before the Hon'ble Bombay High Court.

As at 30th June, 2011, the Company is carrying cumulative provisions of ₹240.50 lakhs in respect of such demands. Although the Company is contesting the demands, it is not possible to predict the outcome of these demands. The management of the Company is of the opinion that the ultimate liability would not exceed the amount provided in the accounts. The auditors' report on the financial statements for the period ended 31st March, 2011 has been qualified in respect of the demands aggregating to ₹5667.22 lakhs (net of provisions of ₹240.50 lakhs).
- (c) The Government of India raised a demand of ₹1726.35 lakhs (inclusive of interest of ₹134.90 lakhs) up to 31st March, 2009 on the Company towards the alleged non compliance of the Order issued under paragraph 8 of DPCO 1995 in respect of the production of Prednisolone based formulations during the period June 2000 to March 2001 and April 2003 to August 2004. The Company has provided and paid amounts aggregating to ₹1287.93 lakhs and disputed the balance demand of ₹438.42 lakhs (inclusive of interest of ₹134.90 lakhs). The matter is pending adjudication before the Hon'ble Bombay High Court. The matter has been qualified in the auditors' report on the financial statements for the period ended 31st March, 2011.
4. During the period, 4 investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the period.

For Wyeth Limited



Kewal Handa
Managing Director
Mumbai, 5th August, 2011

